Adjuvant treatment with immune checkpoint inhibition (PD1) and targeted therapy (TT) with BRAF+MEK inhibitors significantly improved recurrence-free survival (RFS) of stage III melanoma patients.
We investigated efficacy of adjuvant therapy with PD1 or TT under real-world conditions.
